JP2023526247A5 - - Google Patents

Info

Publication number
JP2023526247A5
JP2023526247A5 JP2022568792A JP2022568792A JP2023526247A5 JP 2023526247 A5 JP2023526247 A5 JP 2023526247A5 JP 2022568792 A JP2022568792 A JP 2022568792A JP 2022568792 A JP2022568792 A JP 2022568792A JP 2023526247 A5 JP2023526247 A5 JP 2023526247A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
substituents independently
independently selected
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022568792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526247A (ja
JP7758687B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031989 external-priority patent/WO2021231572A1/en
Publication of JP2023526247A publication Critical patent/JP2023526247A/ja
Publication of JP2023526247A5 publication Critical patent/JP2023526247A5/ja
Application granted granted Critical
Publication of JP7758687B2 publication Critical patent/JP7758687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022568792A 2020-05-13 2021-05-12 神経筋疾患の処置のためのピリダジノン化合物 Active JP7758687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063024442P 2020-05-13 2020-05-13
US63/024,442 2020-05-13
PCT/US2021/031989 WO2021231572A1 (en) 2020-05-13 2021-05-12 Pyridazinone compounds for the treatment of neuromuscular diseases

Publications (3)

Publication Number Publication Date
JP2023526247A JP2023526247A (ja) 2023-06-21
JP2023526247A5 true JP2023526247A5 (enExample) 2024-05-22
JP7758687B2 JP7758687B2 (ja) 2025-10-22

Family

ID=76444536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568792A Active JP7758687B2 (ja) 2020-05-13 2021-05-12 神経筋疾患の処置のためのピリダジノン化合物

Country Status (4)

Country Link
US (1) US20230150977A1 (enExample)
EP (1) EP4149621B1 (enExample)
JP (1) JP7758687B2 (enExample)
WO (1) WO2021231572A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102885525B1 (ko) 2018-11-06 2025-11-13 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
SMT202300355T1 (it) 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4473968A3 (en) 2020-05-13 2025-03-26 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
JP2025530218A (ja) 2022-09-09 2025-09-11 エッジワイズ セラピューティクス， インコーポレイテッド 神経筋の状態の処置のためのピリダジノン組成物
EP4647429A1 (en) * 2023-01-04 2025-11-12 Xizang Haisco Pharmaceutical Co., Ltd. Pyridazinone heterocyclic compound myosin ii inhibitor and use thereof
WO2025153721A1 (en) * 2024-01-19 2025-07-24 Scenic Biotech Bv Pla2g15 inhibitors
WO2025167826A1 (zh) * 2024-02-06 2025-08-14 西藏海思科制药有限公司 三环化合物作为Myosin II抑制剂及其用途
WO2025175141A1 (en) * 2024-02-16 2025-08-21 Cytokinetics, Incorporated Fast skeletal muscle myosin inhibitors
WO2025242154A1 (zh) * 2024-05-23 2025-11-27 西藏海思科制药有限公司 哒嗪酮衍生物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1471515A (zh) 2000-06-05 2004-01-28 ��̹��ҽҩ��˾ 作为β2-肾上腺素受体激动剂及PDE-4抑制剂的有效的化合物
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
CA2676173A1 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
EP3600322A1 (en) 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
WO2019084499A1 (en) * 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION
ES3041367T3 (en) 2018-06-04 2025-11-11 Ohio State Innovation Foundation Eaat2 activators and methods of using thereof
SMT202300355T1 (it) * 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
KR102885525B1 (ko) * 2018-11-06 2025-11-13 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
WO2020097258A1 (en) * 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2022506686A5 (enExample)
JP2023526248A5 (enExample)
JP2022506685A5 (enExample)
JP2024540485A5 (enExample)
DE2922523C2 (de) Aminothiazole und diese enthaltende Arzneimitte l
DE69507199T2 (de) Heterocyclylcarbonylsubstituierte Benzofuranyl- und -thiophenylalkancarbonsäurederivate
DE1518488C3 (de) N-Cyclopropyläthylendiamine und Verfahren zu deren Herstellung
JP2025509438A5 (enExample)
JP2005500297A (ja) ナトリウムチャンネルを調節するイミダゾール誘導体
CH622014A5 (en) Process for the preparation of novel 2-tetrahydrofurfuryl-6,7-benzomorphans
AT394715B (de) Verfahren zur n-alkylierung von harnstoffen
AT392070B (de) Verfahren zur herstellung neuer 1,5-benzothiazepine
JP2017534572A5 (enExample)
JP2024511389A5 (enExample)
JP2023512786A5 (enExample)
JP2021534221A5 (enExample)
SU1344245A3 (ru) Способ получени N- (3- алкиламинопропил) -N @ - фенилмочевины или их фармакологически приемлемых солей /его варианты/
CH621127A5 (enExample)
US4537781A (en) Pharmaceutically useful malonamides
DE2833986A1 (de) Immunstimulierende n-substituierte aziridin-2-carbonsaeurederivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese substanzen enthalten
EP0367164B1 (de) Ammonium- und Immoniumverbindungen und Verfahren zu ihrer Herstellung
DE2542702C2 (de) Verfahren zur Herstellung von 1-Benzoyl-2-(2,6-dichlorphenylamino)-2-imidazolin
US3335147A (en) Anilino-pyridinium-maleimides
EP2179993A1 (de) Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE2213028B2 (de) Dl-3-formylaminothiacyclopentan-2- on-, verfahren zu dessen herstellung und dl-3-formylamino-thiacyclopentan-2-on und andere acylderivate enthaltende pharmazeutische zusammensetzungen